You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).

Figure INF-9:  HBV prevalence among injecting drug users (percentage with HbsAg) – studies with national and subnational coverage, 2002 to 2003

Figure INF-09

Notes:

Black square = samples with national coverage; blue triangle = samples with subnational (including local or regional) coverage.

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Portugal include non-IDUs and therefore may underestimate prevalence among IDUs (proportion of non-IDUs in the samples not known).

Data for Portugal are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

Sources:

Reitox national focal points. For primary sources, study details and data before 2002, see [Table INF-14] in the 2005 statistical bulletin.